|  |  |  | **Vaccine brand** | | | |
| --- | --- | --- | --- | --- | --- | --- |
|  |  |  | **Moderna** | | **Pfizer** | |
|  |  |  | **Exposed** | | | |
| Variable name | Variable level | Estimate name | Unexposed | Exposed | Unexposed | Exposed |
| Number records | - | N | 2,086 | 2,086 | 897 | 897 |
| Age | - | Median [Q25 - Q75] | 34.00 [31.00 - 37.00] | 34.00 [31.00 - 37.00] | 33.00 [30.00 - 37.00] | 33.00 [30.00 - 37.00] |
| Age group | 12 to 24 | N (%) | 53 (2.5%) | 52 (2.5%) | 56 (6.2%) | 57 (6.4%) |
|  | 25 to 39 | N (%) | 1,794 (86.0%) | 1,792 (85.9%) | 752 (83.8%) | 754 (84.1%) |
|  | 40 to 55 | N (%) | 239 (11.5%) | 242 (11.6%) | 89 (9.9%) | 86 (9.6%) |
| Vaccine brand | Moderna | N (%) | 2,086 (100.0%) | 2,086 (100.0%) | - | - |
|  | Pfizer | N (%) | - | - | 897 (100.0%) | 897 (100.0%) |
| Trimester | Trimester 1 | N (%) | 649 (31.1%) | 645 (30.9%) | 228 (25.4%) | 229 (25.5%) |
|  | Trimester 2 | N (%) | 917 (44.0%) | 917 (44.0%) | 371 (41.4%) | 376 (41.9%) |
|  | Trimester 3 | N (%) | 520 (24.9%) | 524 (25.1%) | 298 (33.2%) | 292 (32.6%) |
| Number visits prior year | - | Median [Q25 - Q75] | 19.00 [10.00 - 35.00] | 33.50 [16.00 - 56.00] | 19.00 [10.00 - 32.00] | 34.00 [18.00 - 54.00] |
| Number prior pregnancies | - | Median [Q25 - Q75] | 1.00 [1.00 - 2.00] | 2.00 [2.00 - 2.00] | 1.00 [1.00 - 2.00] | 2.00 [2.00 - 2.00] |
| Conditions any time prior | Anemia | N (%) | 381 (18.3%) | 368 (17.6%) | 199 (22.2%) | 193 (21.5%) |
|  | Heart conditions | N (%) | 51 (2.4%) | 50 (2.4%) | 26 (2.9%) | 22 (2.5%) |
|  | Eclampsia preeclampsia | N (%) | 21 (1.0%) | 27 (1.3%) | 9 (1.0%) | 9 (1.0%) |
|  | Asthma | N (%) | 116 (5.6%) | 137 (6.6%) | 57 (6.4%) | 62 (6.9%) |
|  | Pneumonia | N (%) | 55 (2.6%) | 54 (2.6%) | 25 (2.8%) | 23 (2.6%) |
|  | Hypothyroidism | N (%) | 193 (9.3%) | 210 (10.1%) | 69 (7.7%) | 96 (10.7%) |
|  | Depressive disorder | N (%) | 110 (5.3%) | 117 (5.6%) | 53 (5.9%) | 43 (4.8%) |
|  | Gestational diabetes | N (%) | 94 (4.5%) | 91 (4.4%) | 53 (5.9%) | 47 (5.2%) |
|  | Chronic hypertension | N (%) | 47 (2.3%) | 55 (2.6%) | 17 (1.9%) | 19 (2.1%) |
|  | Anxiety disorder | N (%) | 572 (27.4%) | 555 (26.6%) | 244 (27.2%) | 219 (24.4%) |
|  | Chronic obstructive lung disease | N (%) | <5 (<5%) | 5 (0.2%) | <5 (<5%) | <5 (<5%) |
| Drugs prior 180 days | Propulsives | N (%) | 67 (3.2%) | 44 (2.1%) | 35 (3.9%) | 27 (3.0%) |
|  | Progestogens | N (%) | 129 (6.2%) | 128 (6.1%) | 54 (6.0%) | 46 (5.1%) |
|  | Antimycotics systemic | N (%) | 6 (0.3%) | 7 (0.3%) | 6 (0.7%) | 5 (0.6%) |
|  | Estrogens | N (%) | 124 (5.9%) | 117 (5.6%) | 49 (5.5%) | 49 (5.5%) |
|  | Antithrombotics | N (%) | 246 (11.8%) | 132 (6.3%) | 93 (10.4%) | 64 (7.1%) |
|  | Antihistamines systemic | N (%) | 318 (15.2%) | 305 (14.6%) | 135 (15.1%) | 182 (20.3%) |
|  | Antidepressants | N (%) | 97 (4.7%) | 105 (5.0%) | 50 (5.6%) | 40 (4.5%) |
|  | Immunoglobulins | N (%) | 77 (3.7%) | 82 (3.9%) | 39 (4.3%) | 28 (3.1%) |
|  | Analgesics and antipyretics | N (%) | 701 (33.6%) | 621 (29.8%) | 336 (37.5%) | 349 (38.9%) |
|  | Antiinflammatory antirehumatic | N (%) | 348 (16.7%) | 318 (15.2%) | 141 (15.7%) | 170 (19.0%) |
|  | Antiepileptics | N (%) | 27 (1.3%) | 28 (1.3%) | 10 (1.1%) | 16 (1.8%) |
|  | Antibacterials systemic | N (%) | 452 (21.7%) | 396 (19.0%) | 189 (21.1%) | 193 (21.5%) |